Browsing Øvrige samlinger by Author "Pabinger, Ingrid"
Now showing items 1-3 of 3
-
Lalezari, Shadan; Reding, Mark T.; Pabinger, Ingrid; Holme, Pål Andre; Negrier, Claude; Chalasani, Pavani; Shin, Ho-Jin; Wang, Maria; Tseneklidou-Stoeter, Despina; Enriquez, Monika Maas (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)Introduction BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval ...
-
Reding, Mark T.; Pabinger, Ingrid; Holme, Pål Andre; Poulsen, Lone; Negrier, Claude; Chalasani, Pavani; Maas Enriquez, Monika; Wang, Maria; Meijer, Karina; Mancuso, Maria Elisa; Lalezari, Shadan (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)Introduction The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to extend ...
-
Reding, Mark T.; Pabinger, Ingrid; Holme, Pål Andre; Maas Enriquez, Monika; Mancuso, Maria Elisa; Lalezari, Shadan; Miesbach, Wolfgang; Di Minno, Giovanni; Klamroth, Robert; Hermans, Cedric (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have ...